Litcius/Paper detail

Characterization of Aminobenzylphenols as Protein Disulfide Isomerase Inhibitors in Glioblastoma Cell Lines

Andrea Shergalis, Ding Xue, Fatma Z. Gharbia, Hannah Driks, Binita Shrestha, Amina Tanweer, Kirin Cromer, Mats Ljungman, Nouri Neamati

2020Journal of Medicinal Chemistry20 citationsDOIOpen Access PDF

Abstract

Disulfide bond formation is a critical post-translational modification of newly synthesized polypeptides in the oxidizing environment of the endoplasmic reticulum and is mediated by protein disulfide isomerase (PDIA1). In this study, we report a series of α-aminobenzylphenol analogues as potent PDI inhibitors. The lead compound, AS15, is a covalent nanomolar inhibitor of PDI, and the combination of AS15 analogues with glutathione synthesis inhibitor buthionine sulfoximine (BSO) leads to synergistic cell growth inhibition. Using nascent RNA sequencing, we show that an AS15 analogue triggers the unfolded protein response in glioblastoma cells. A BODIPY-labeled analogue binds proteins including PDIA1, suggesting that the compounds are cell-permeable and reach the intended target. Taken together, these findings demonstrate an extensive biochemical characterization of a novel series of highly potent reactive small molecules that covalently bind to PDI.

Topics & Concepts

Protein disulfide-isomeraseChemistryEndoplasmic reticulumBiochemistryCovalent bondCysteineGlutathioneEnzymeSmall moleculeButhionine sulfoximineOrganic chemistryEndoplasmic Reticulum Stress and DiseaseAutophagy in Disease and TherapyAdenosine and Purinergic Signaling
Characterization of Aminobenzylphenols as Protein Disulfide Isomerase Inhibitors in Glioblastoma Cell Lines | Litcius